References
- 1. W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek and G. Palareti, Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest141 (2012) e44S-88S; DOI: 10.1378/chest.11-2292.
- 2. A. Mavri and G. Tratar, Kakovost vodenja antikoagulacijskega zdravljenja v Sloveniji [Quality of the management of anticoagulant therapy in Slovenia], ISIS16 (2007) 56–59.
- 3. A. J. Camm, G. Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S. H. Hohnloser, G. Hindricks and P. Kirchhof, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur. Heart J.33 (2012) 2719–2747; DOI: 10.1093/eurheartj/ehs253.
- 4. R. G. Hart, L. A. Pearce and M. I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann. Intern. Med.146 (2007) 857–867; DOI: 10.7326/0003-4819-146-12-200706190-00007.
- 5. S. J. Wilson, P. S. Wells, M. J. Kovacs, G. M. Lewis, J. Martin, E. Burton and D. R. Anderson, Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial, CMAJ169 (2003) 293–298.
- 6. C. J. Heneghan, J. M. Garcia-Alamino, E. A. Spencer, A. M. Ward, R. Perera, C. Bankhead, P. Alonso-Coello, D. Fitzmaurice, K. R. Mahtani and I. J. Onakpoya, Self-monitoring and self-management of oral anticoagulation, Cochrane Database Syst. Rev.7 (2016) CD003839; DOI: 10.1002/14651858.CD003839.pub3.
- 7. S. Testa, O. Paoletti, A. Zimmermann, L. Bassi, S. Zambelli and E. Cancellieri, The role of anticoagulation clinics in the era of new oral anticoagulants, Thrombosis2012 (2012) Article ID 835356, 6 pages; DOI: 10.1155/2012/835356.
- 8. G. D. Barnes, B. K. Nallamothu, A. E. Sales and J. B. Froehlich, Reimagining anticoagulation clinics in the era of direct oral anticoagulants, Circ. Cardiovasc. Qual. Outcomes9 (2016) 182–185; DOI: 10.1161/Circoutcomes.115.002366.
- 9. A. Janzic and M. Kos, Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control, Pharmacoeconomics33 (2015) 395–408; DOI: 10.1007/s40273-014-0246-7.
- 10. N. L. Liberato and M. Marchetti, Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review, Expert Rev. Pharmacoecon. Outcomes Res.16 (2016) 221–235; DOI: 10.1586/14737167.2016.1147351.
- 11. R. E. Malmstrom, B. B. Godman, E. Diogene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, A. Bucsics, S. Campbell, A. Ferrario, A. E. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffmann, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. A. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Markovic-Pekovic, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulunay, D. Tomek, L. Voncina, V. Vlahovic-Palcevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara and L. L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Front. Pharmacol.4 (2013) Article ID 39; DOI: 10.3389/fphar.2013.00039.
- 12. B. Godman, R. E. Malmstrom, E. Diogene, A. Gray, S. Jayathissa, A. Timoney, F. Acurcio, A. Alkan, A. Brzezinska, A. Bucsics, S. M. Campbell, J. Czeczot, W. de Bruyn, I. Eriksson, F. A. Yusof, A. E. Finlayson, J. Furst, K. Garuoliene, A. Guerra Junior, J. Gulbinovic, S. Jan, R. Joppi, M. Kalaba, E. Magnisson, L. McCullagh, K. Miikkulainen, G. Ofierska-Sujkowska, H. B. Pedersen, G. Selke, C. Sermet, S. Spillane, A. Supian, I. Truter, V. Vlahovic-Palcevski, L. E. Vien, E. H. Vural, J. Wale, M. Wladysiuk, W. Zeng and L. L. Gustafsson, Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?, Expert. Rev. Clin. Pharmacol.8 (2015) 77–94; DOI: 10.1586/17512433.2015.990380.
- 13. B. Godman, R. E. Malmstrom, E. Diogene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. B. Pedersen, V. Markovic-Pekovic, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Voncina, V. Vlahovic-Palcevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara and L. L. Gustafsson, Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Front. Pharmacol.5 (2014) Article ID 109; DOI: 10.3389/fphar.2014.00109.
- 14. T. Wilke, A. Groth, S. Mueller, M. Pfannkuche, F. Verheyen, R. Linder, U. Maywald, T. Kohlmann, Y. S. Feng, G. Breithardt and R. Bauersachs, Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients, Thromb. Haemost.107 (2012) 1053–1065; DOI: 10.1160/TH11-11-0768.
- 15. T. C. Sarich, J. H. Seltzer, S. D. Berkowitz, J. Costin, J. T. Curnutte, C. M. Gibson, M. Hoffman, E. Kaminskas, M. W. Krucoff, J. H. Levy, P. D. Mintz, P. A. Reilly, P. T. Sager, D. E. Singer, N. Stockbridge, J. I. Weitz and P. R. Kowey, Novel oral anticoagulants and reversal agents: Considerations for clinical development, Am. Heart J.169 (2015) 751–757; DOI: 10.1016/j.ahj.2015.03.010.